A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations.
- Resource Type
- Article
- Source
- Cell Reports; Jul2021, Vol. 36 Issue 4, pN.PAG-N.PAG, 1p
- Subject
- Language
- ISSN
- 26391856